St. Louis-based biotech firm C2N Diagnostics gets $10M investment from Samsung
A St. Louis-based company known for its work in Alzheimer's and neurological testing can expand its footprint, thanks to a $10 million investment from several life sciences companies.
Samsung Invests in C2N Diagnostics
C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, today ...
Fierce Biotech5d
Samsung backs Alzheimer's blood test developer C2N Diagnostics with $10M
Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...
Business Wire1mon
First Canadian Clinic to Offer C2N’s PrecivityAD2™ Blood Test to Help Healthcare Providers Diagnose Alzheimer’s Disease, Joining Global Community in Embracing ...
Toronto Memory Program (TMP) is the first clinic in the country to offer the PrecivityAD2™ blood test from C2N Diagnostics, LLC (“C2N”). This blood test allows healthcare providers to ...
Morningstar5d
Samsung Invests in C2N Diagnostics
it has contributed to the stabilization of the biopharmaceutical supply chain and better access to high quality bio pharmaceutics. The investment into C2N Diagnostics shows Samsung’s continued ...